A Phase 4 interventional study of olaparib and enzalutamide in Metastatic Castration-resistant Prostate Cancer, sponsored by AstraZeneca. Active, not recruiting at 35 sites in China. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-21.
Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing olaparib in Prostatic Neoplasms — 2 open to participants now, 11 under way, 2 of them phase 3. olaparib · Prostatic Neoplasms.
Among the 25 studies testing olaparib in Prostatic Neoplasms, this one is the 13th largest by enrollment, is one of 2 that started in 2022, is the only one in phase 4, reaches primary completion later than 3 of the 10 other live ones, and was the 21st registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →2 of the 25 studies testing olaparib in Prostatic Neoplasms are open now, in 1 country. Recruiting first, the newest first:
Zin W Myint · Sites in United States
Ages 18+ · Men only
VA Office of Research and Development · Sites in United States
Ages 18+ · Men only
By country, each count listing its studies:
olaparib: first FDA approval 2014 (LYNPARZA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, olaparib is the treatment under test here. Read study by study →
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 16 · Phase 3 4 · Phase 4 1
First in 2014; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 43 is below the median of 60 across 5,352 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 43 across the 25 interventional studies. Of the 10 that completed or were terminated, 7 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 25 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,504 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
91 studies in Prostatic Neoplasms by AstraZeneca: 15 open now, 29 under way, 8 of them phase 3. Of 58 finished, 11 (19%) have results posted.
Among the 91 studies in Prostatic Neoplasms by AstraZeneca, this one is the 44th largest by enrollment of the 60 interventional ones that give a count, is one of 4 that started in 2022, is one of 4 in phase 4, reaches primary completion later than 2 of the 28 other live ones, and was the 68th registered.
AstraZeneca’s Prostatic Neoplasms studies by the year they started, since 1994.
2 of the studies testing olaparib in Prostatic Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04038502VA Office of Research and DevelopmentCarboplatin or Olaparib for BRcA Deficient Prostate Cancer | 2027-08-31 |
| NCT02861573Merck Sharp & Dohme LLCStudy of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) | 2027-10-22 |
Add all 2 to your calendar (.ics) → With an account.
Among the 25 studies testing olaparib in Prostatic Neoplasms, from their registry updates:
Among AstraZeneca’s 91 in Prostatic Neoplasms:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of Olaparib compared with standard of care (Enzalutamide or Abiraterone Acetate) in Chinese men with metastatic castration-resistant prostate cancer who have failed prior treatment with a new hormonal agent and have BRCA1/2 mutations.
This is a Phase IV, randomized, open-label, 2-arm, multicenter study evaluating the efficacy and safety of olaparib in Chinese men with metastatic castration-resistant prostate cancer (mCRPC) who have failed prior treatment with a new hormonal agent (NHA) and have BRCA1/2 mutations. Approximately 42 subjects will be randomized in a 2:1 ratio to olaparib or to investigator's choice of NHA (enzalutamide or abiraterone acetate).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Olaparib is available as a film-coated tablet containing 150 mg or 100 mg of olaparib. Subjects will be administered study treatment orally at a dose of 300 mg twice daily (bid). The planned dose of 300 mg bid will be made up of two x 150 mg tablets twice daily, with 100 mg tablets used to manage dose reductions
Drug: olaparib
Enzalutamide: Enzalutamide is available as capsules or tablets containing 40 mg of enzalutamide. Subjects will be administered study treatment orally at a dose of 160 mg once daily. Abiraterone acetate with prednisone: Abiraterone acetate is available as tablets containing 250 mg of abiraterone acetate. Subjects will be administered study treatment orally at a dose of 1,000 mg once daily. Prednisone is 5mg twice daily. Prednisolone is permitted for use instead of prednisone if necessary.
Drug: enzalutamide · Drug: abiraterone acetate · Drug: Prednisone
300 mg (2x 150 mg tablets) twice daily
Also known as: Lynparza
160 mg (4 x 40 mg capsules) once daily
Also known as: XTANDI
1,000 mg (4 x 250 mg tablets) once daily
Also known as: ZYTIGA
5mg(5mg x 1 tablet) twice daily
Radiological Progression-free Survival - Based on Blinded Independent Central Review (BICR)
rPFS is defined as the time from randomization until the date of objective disease progression (soft tissue or bone) or death (by any cause in the absence of progression) regardless of whether the patient withdraws from randomized therapy or receives another anti-cancer therapy prior to progression.
Time frame: Tumor assessments every 8 weeks (± 1 week) relative to the date of randomization until radiological progression as assessed by BICR or death (median duration of treatment of 9 and 6 months for Olaparib and Investigators Choice of NHA respectively).
Confirmed Objective Response Rate (ORR), Based on Blinded Independent Review (BICR)
Confirmed ORR is the percentage of patients with a Complete response (CR) or Partial response (PR), in their soft tissue disease per (RECIST v1.1), in the absence of progression on bone scan per Prostate Cancer Working Group 3 (PCWG3), confirmed \>=4 weeks later. Per RECIST v1.1, CR=Disappearance of all target lesions; PR = \>=30% decrease in the sum of diameters of target lesions. For each treatment group, confirmed ORR is the number of patients with a confirmed CR or PR divided by the number of patients in the treatment group.
Time frame: Tumor assessments every 8 weeks (± 1 week) from randomisation until radiographic progression assessed by BICR (median duration of treatment of 9 and 6 months for Olaparib and Investigators Choice of NHA respectively).
Overall Survival
OS is the time from the date of randomization until death due to any cause.
Time frame: From the time from the date of randomization until death due to any cause. Assessments continue up to 27 months after the first patient was randomized.
Time to First Symptomatic Skeletal-related Event
Time from first dose to the first symptomatic skeletal-related event
Time frame: Time from randomization to the first SSRE-radiation for skeletal symptoms, confirmed pathological fracture, confirmed spinal cord compression, or orthopaedic surgery for bone metastases. Assessments continue up to 27 months post first patient enrolled.
Time to Opiate Use for Cancer-related Pain
Time from randomization to opiate use for cancer-related pain
Time frame: Opioid use will be recorded at baseline and at every study visit, including the safety follow-up visit. Assessments continue up to 27 months post first patient enrolled.
Prostate-specific Antigen Response
Proportion of participants achieving a ≥50% decrease in PSA from baseline to the lowest post-baseline PSA result, confirmed by a second consecutive PSA assessment at least 3 weeks later (PSA50 response)
Time frame: Blood samples for PSA assessment will be collected at baseline and every 4 weeks throughout the treatment phase, including at the study treatment discontinuation visit. Assessments continue up to 27 months post first patient enrolled.
Prostate-specific Antigen Response
Best percentage change from baseline in PSA is defined as the biggest reduction in PSA level compared with baseline (or the smallest increase in the absence of a reduction) taking account of all PSA values collected for each patient.
Time frame: Blood samples for PSA assessment will be collected at baseline and every 4 weeks throughout the treatment phase, including at the study treatment discontinuation visit. Assessments continue up to 27 months post first patient enrolled.
Time From Randomization to Second Progression or Death
Time from randomization to second progression by investigator assessment of radiological or clinical progression or death (PFS2)
Time frame: Tumor assessments will be performed every 8 weeks (±7 days) after randomization until radiologic progression or death, unless the participant withdraws consent. Assessments continue up to 27 months post first patient enrolled.
Subsequent Anticancer Therapy
Time frame: Recorded from post discontinuation of study treatment up to primary data cut off date. Assessments continue up to 27 months post first patient enrolled.
| Milestone | Olaparib 300 mg bd | Investigators Choice of NHA |
|---|---|---|
| Started | 29 | 14 |
| Completed | 0 | 0 |
| Not completed | 29 | 14 |
| Withdrew: Withdrawal by subject | 0 | 2 |
| Withdrew: Death | 10 | 3 |
| Withdrew: Ongoing | 19 | 9 |
rPFS is defined as the time from randomization until the date of objective disease progression (soft tissue or bone) or death (by any cause in the absence of progression) regardless of whether the patient withdraws from randomized therapy or receives another anti-cancer therapy prior to progression.
| Months | Olaparib 300 mg bd | Investigators Choice of NHA |
|---|---|---|
| Radiological Progression-free Survival - Based on Blinded Independent Central Review (BICR) | 9.331 (5.65 to 11.20) | 8.838 (1.77 to NA) |
Confirmed ORR is the percentage of patients with a Complete response (CR) or Partial response (PR), in their soft tissue disease per (RECIST v1.1), in the absence of progression on bone scan per Prostate Cancer Working Group 3 (PCWG3), confirmed \>=4 weeks later. Per RECIST v1.1, CR=Disappearance of all target lesions; PR = \>=30% decrease in the sum of diameters of target lesions. For each treatment group, confirmed ORR is the number of patients with a confirmed CR or PR divided by the number of patients in the treatment group.
| Participants | Olaparib 300 mg bd | Investigators Choice of NHA |
|---|---|---|
| Confirmed Objective Response Rate (ORR), Based on Blinded Independent Review (BICR) | 5 | 1 |
OS is the time from the date of randomization until death due to any cause.
| Months | Olaparib 300 mg bd | Investigators Choice of NHA |
|---|---|---|
| Overall Survival | 17.314 (13.90 to NA) | NA (10.32 to NA) |
Time from first dose to the first symptomatic skeletal-related event
| Months | Olaparib 300 mg bd | Investigators Choice of NHA |
|---|---|---|
| Time to First Symptomatic Skeletal-related Event | NA (NA to NA) | NA (NA to NA) |
Time from randomization to opiate use for cancer-related pain
| Months | Olaparib 300 mg bd | Investigators Choice of NHA |
|---|---|---|
| Time to Opiate Use for Cancer-related Pain | NA (11.20 to NA) | 17.281 (1.31 to NA) |
Proportion of participants achieving a ≥50% decrease in PSA from baseline to the lowest post-baseline PSA result, confirmed by a second consecutive PSA assessment at least 3 weeks later (PSA50 response)
| Percentage of participants | Olaparib 300 mg bd | Investigators Choice of NHA |
|---|---|---|
| Single visit response | 48 (29 to 67) | 36 (13 to 65) |
| Confirmed response | 41 (24 to 61) | 29 (8 to 58) |
Best percentage change from baseline in PSA is defined as the biggest reduction in PSA level compared with baseline (or the smallest increase in the absence of a reduction) taking account of all PSA values collected for each patient.
| Percentage change from baseline | Olaparib 300 mg bd | Investigators Choice of NHA |
|---|---|---|
| Percentage change from baseline at Week 12 | 37.2 ± 252.62 | -15.0 ± 53.84 |
| Best percentage change from baseline | -40.6 ± 60.06 | -22.7 ± 74.62 |
Time from randomization to second progression by investigator assessment of radiological or clinical progression or death (PFS2)
| Months | Olaparib 300 mg bd | Investigators Choice of NHA |
|---|---|---|
| Time From Randomization to Second Progression or Death | NA (15.41 to NA) | NA (5.91 to NA) |
| Participants | Olaparib 300 mg bd | Investigators Choice of NHA |
|---|---|---|
| Any post-discontinuation anti-cancer therapy | 14 | 3 |
| Immunotherapy | 0 | 0 |
| Hormonal therapy | 12 | 2 |
| Taxane chemotherapy | 4 | 0 |
| Platinum chemotherapy | 0 | 0 |
| PARP inhibitor | 0 | 3 |
| Other | 1 | 0 |
Collected over From the time of signature of the ICF, throughout the treatment period and until the 30-day follow-up period is completed or 27 months post first patient enrolled, whichever occurs earlier. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Olaparib 300mg bd | 10/29 (34.5%) | 13/29 (44.8%) | 28/29 (96.6%) |
| Investigators Choice of NHA | 3/14 (21.4%) | 5/14 (35.7%) | 13/14 (92.9%) |
| Event | Olaparib 300mg bd | Investigators Choice of NHA |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 4/29 | 0/14 |
| Decreased appetiteMetabolism and nutrition disorders | 3/29 | 1/14 |
| OsteomyelitisInfections and infestations | 0/29 | 1/14 |
| Pituitary tumour benignNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/29 | 1/14 |
| HaematuriaRenal and urinary disorders | 0/29 | 1/14 |
| Urinary retentionRenal and urinary disorders | 0/29 | 1/14 |
| Deep vein thrombosisVascular disorders | 0/29 | 1/14 |
| Cardiac failureCardiac disorders | 0/29 | 1/14 |
| VomitingGastrointestinal disorders | 1/29 | 0/14 |
| FatigueGeneral disorders | 1/29 | 0/14 |
| Event | Olaparib 300mg bd | Investigators Choice of NHA |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 22/29 | 5/14 |
| VomitingGastrointestinal disorders | 7/29 | 4/14 |
| ConstipationGastrointestinal disorders | 7/29 | 3/14 |
| Weight decreasedInvestigations | 7/29 | 3/14 |
| White blood cell count decreasedInvestigations | 7/29 | 3/14 |
| HyponatraemiaMetabolism and nutrition disorders | 7/29 | 3/14 |
| Urinary tract infectionInfections and infestations | 2/29 | 3/14 |
| Neutrophil count decreasedInvestigations | 6/29 | 3/14 |
| Platelet count decreasedInvestigations | 6/29 | 3/14 |
| HypercholesterolaemiaMetabolism and nutrition disorders | 0/29 | 3/14 |
| Age, Continuous(Years) | Olaparib 300 mg bd | Investigators Choice of NHA | Total |
|---|---|---|---|
| Median | 68.0 (56 to 82) | 67.5 (52 to 75) | 68.0 (52 to 82) |
| Sex: Female, Male(Participants) | Olaparib 300 mg bd | Investigators Choice of NHA | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 29 | 14 | 43 |
| Ethnicity (NIH/OMB)(Participants) | Olaparib 300 mg bd | Investigators Choice of NHA | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 29 | 14 | 43 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Olaparib 300 mg bd | Investigators Choice of NHA | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 29 | 14 | 43 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment(https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure). "Yes" indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved, AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access.For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Jul 2022 to primary completion in Oct 2024, 26 months.
Results were first posted in Dec 2025, 1 year 1 month after primary completion.
Of 52 phase 4 interventional studies under Prostatic Neoplasms, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 67. This study's 26 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Olaparib